In experimental HUS, treatment with a C3a receptor (C3aR) antagonist counteracted glomerular endothelial and podocyte injury and restored renal function, thus identifying C3a as a key player in the development of kidney injury in HUS [22,23]. The gene discussed is C3; the disease is hemolytic-uremic syndrome.